Abstract

Vancomycin-resistant "Staphylococcus aureus" are strains of "Staphylococcus aureus" that have become resistant to the glycopeptide antibiotic vancomycin.

Mechanism of acquired resistance

Strains of hVISA and VISA do not have resistant genes found in "Enterococcus" and the proposed mechanisms of resistance include the sequential mutations resulting in a thicker cell wall and the synthesis of excess amounts of D-ala-D-ala residues. VRSA strain acquired the vancomycin resistance gene cluster "vanA" from VRE.

Diagnosis

The diagnosis of vancomycin-resistant Staphylococcus aureus can be done with disk diffusion(and VA screen plate)

Treatment of infection

For isolates with a Vancomycin MIC , an alternative to Vancomycin should be used. The approach is to treat with at least one agent to which VISA/VRSA is known to be susceptible by "in vitro" testing. The agents that are used include daptomycin, linezolid, telavancin, ceftaroline, quinupristin–dalfopristin. For people with MRSA bacteremia in the setting of vancomycin failure the IDSA recommends high-dose daptomycin, if the isolate is susceptible, in combination with another agent (e.g. gentamicin, rifampin, linezolid, TMP-SMX, or a beta-lactam antibiotic).

History

Three classes of vancomycin-resistant "S. aureus" have emerged that differ in vancomycin susceptibilities: vancomycin-intermediate "S. aureus" (VISA), heterogeneous vancomycin-intermediate "S. aureus" (hVISA), and high-level vancomycin-resistant "S. aureus" (VRSA).

History | Vancomycin-intermediate "S. aureus"(VISA)

VISA ( or ) was first identified in Japan in 1996 and has since been found in hospitals elsewhere in Asia, as well as in the United Kingdom, France, the U.S., and Brazil. It is also termed GISA (glycopeptide-intermediate "Staphylococcus aureus"), indicating resistance to all glycopeptide antibiotics. These bacterial strains present a thickening of the cell wall, which is believed to reduce the ability of vancomycin to diffuse into the division septum of the cell required for effective vancomycin treatment.

History | Vancomycin-resistant "S. aureus" (VRSA)

High-level vancomycin resistance in "S. aureus" has been rarely reported. "In vitro" and "in vivo" experiments reported in 1992 demonstrated that vancomycin resistance genes from "Enterococcus faecalis" could be transferred by gene transfer to "S. aureus", conferring high-level vancomycin resistance to "S. aureus". Until 2002 such a genetic transfer was not reported for wild "S. aureus" strains. In 2002, a VRSA strain ( or ) was isolated from a patient in Michigan. The isolate contained the "mecA" gene for methicillin resistance. Vancomycin MICs of the VRSA isolate were consistent with the VanA phenotype of "Enterococcus" species, and the presence of the "vanA" gene was confirmed by polymerase chain reaction. The DNA sequence of the VRSA "vanA" gene was identical to that of a vancomycin-resistant strain of "Enterococcus faecalis" recovered from the same catheter tip. The "vanA" gene was later found to be encoded within a transposon located on a plasmid carried by the VRSA isolate. This transposon, Tn"1546", confers "vanA"-type vancomycin resistance in enterococci.

History | Heterogeneous vancomycin-intermediate S. aureus (hVISA)

The definition of hVISA according to Hiramatsu et al. is a strain of Staphylococcus aureus that gives resistance to vancomycin at a frequency of 10 colonies or even higher.